Self-Pay Options for TMS: Costs, Financing, and Why Some Patients Choose This Path

Self-pay is a legitimate route to TMS therapy for patients whose plans do not cover the treatment, whose out-of-pocket exposure under coverage would exceed the cash price, or who prefer to keep a record of psychiatric treatment off their insurance file. In published clinical-registry and real-world economics data, self-pay course pricing for a standard acute-phase rTMS series has historically fallen in the $8,000–$15,000 range, with substantial variation by region, device, and clinic.¹ The figure is a national benchmark, not a clinic-specific quote — and the practical first step for nearly every patient is still insurance verification, because the cash decision only becomes clear once the coverage picture is settled. This article describes the patient situations in which self-pay actually makes sense, what a self-pay TMS course typically covers, the financing structures used in psychiatric practice, and the decision framework that puts verification ahead of the price question.

Why insurance verification comes first

Self-pay is the answer after coverage is characterized, not before. Medicare coverage for transcranial magnetic stimulation is governed by Local Coverage Determinations (LCDs) issued by the Medicare Administrative Contractors — there is no National Coverage Determination — and most major commercial payers and Medicare cover TMS for major depressive disorder when medical-necessity criteria are documented.² In practice, that means most patients with a clinical picture consistent with treatment-resistant depression qualify for covered treatment. The cash-pay conversation begins only when verification produces one of a small number of well-defined patterns:

• The plan does not include the relevant TMS CPT codes (90867, 90868, 90869) as a covered benefit.
• The plan covers TMS in principle but the patient does not meet the carrier's documented medical-necessity criteria, and an appealable path has been exhausted.
• The covered, in-network out-of-pocket exposure (deductible plus coinsurance to the out-of-pocket maximum) equals or exceeds the self-pay course price.
• The clinic is out-of-network with the patient's plan and a single-case agreement is not available.
• The patient has a documented preference for keeping the treatment off their insurance record.

Without verification, the patient does not actually know which of these is true. A verification result documents which path is rational; a price quote in the absence of verification can only guess.

Who chooses self-pay — four patient archetypes

In practice, self-pay TMS patients tend to fall into one of four clinical-administrative profiles. No individual case is described here; these are the patterns the verification team sees recur.

The high-deductible profile

A patient with a high-deductible health plan early in the plan year may find that, even though TMS is a covered benefit, the deductible plus coinsurance over a 36-session course will run close to — or above — the self-pay course price. In that situation, paying cash buys two things the insurance route does not: a known total at the start of the course, and freedom from the prior-authorization documentation requirements. The verification report is what makes this comparison concrete; without it, the comparison is hypothetical.

The out-of-network profile

A patient whose preferred clinic is out-of-network with their plan may have nominal out-of-network benefits, but the negotiated rate is the patient's responsibility up to whatever the plan eventually pays, and out-of-network out-of-pocket maximums are typically materially higher than in-network. Some clinics will pursue a single-case agreement with the carrier where the in-network panel has no clinically appropriate alternative; where that is not available, self-pay can be the cleaner path.

The denied-but-clinically-appropriate profile

A small subset of patients meet broad clinical indications for TMS but receive a coverage denial that survives appeal — typically over a carrier-specific criterion the documentation cannot satisfy (for example, a lifetime medication-trial count that exceeds the FDA-cleared indication baseline). Where the treating psychiatrist judges the treatment appropriate and the patient elects to proceed, self-pay is the available route.

The privacy-preference profile

Some patients elect not to submit psychiatric treatment to an insurance carrier for documented privacy or professional-disclosure reasons. The trade-off is paid entirely by the patient; the clinical record is then held only by the treating clinician and the patient. This is a less common pattern than the first three but is a recurring reason patients ask about self-pay.

What a self-pay TMS course actually covers

A self-pay course quote is not a per-session price multiplied by 36. The fee structure at most psychiatric practices covers the full clinical service:

• The initial psychiatric evaluation that establishes the diagnosis, characterizes the current episode, and documents candidacy for TMS.
• The motor-threshold determination and treatment-coil mapping session (CPT 90867 when billed insurance-side), which calibrates stimulation intensity to the individual patient's cortex.
• The acute-phase treatment course — typically 30 to 36 daily sessions over six to nine weeks, depending on protocol (10 Hz rTMS, intermittent theta-burst stimulation, or other FDA-cleared protocol).
• Taper sessions at the end of the acute phase, where the protocol calls for them.
• Ongoing clinical oversight by the treating psychiatrist — periodic rating-scale review, dose-and-frequency adjustment, and the response evaluation that determines whether the acute phase has produced remission, partial response, or non-response.

When comparing self-pay quotes across clinics, the line items above are the apples-to-apples comparison; a quote that excludes motor-threshold mapping, the initial evaluation, or clinical oversight is not a complete course price.

Financing structures used in psychiatric practice

Self-pay does not necessarily mean a single lump-sum payment. Several financing structures are routine in psychiatric practice generally:

Internal payment plans

Many clinics offer an in-house payment plan that schedules the course cost across the treatment window — often with a deposit at the start and installments timed to the weekly session rhythm. Internal plans are typically interest-free, but terms vary by clinic and should be documented in writing before treatment begins.

Third-party medical-credit accounts

Several third-party lenders specialize in medical-procedure financing — generically referred to as medical-credit accounts. These products offer revolving or installment credit dedicated to healthcare expenses, often with a promotional interest-free period (commonly 6 to 24 months) followed by a standard credit-card APR if the balance is not paid in full within the promotional window. Patients considering a medical-credit product should read the deferred-interest terms carefully; the promotional rate is conditional on full payoff within the stated period.

HSA and FSA funds

Funds in a Health Savings Account (HSA) or Flexible Spending Account (FSA) can be used for TMS treatment when the treatment is for a qualifying medical condition; the IRS lists psychiatric care and treatment for mental illness as qualifying medical expenses under Publication 502.³ HSA contributions reduce taxable income at the federal level and the funds roll over year to year; FSA funds are typically use-it-or-lose-it within the plan year. Either account can be paired with a payment plan or medical-credit account so that course costs are paid with pre-tax dollars. Patients should retain itemized receipts from the clinic for substantiation.

Employer wellness and mental-health benefits

A small but growing share of employers offer mental-health stipends or supplemental wellness benefits that can be applied toward psychiatric procedures not covered by the primary health plan. These are typically administered separately from the medical plan and have their own documentation requirements; the patient's HR or benefits portal is the practical starting point.

The decision framework

The order of operations matters more than the absolute dollar figure.

1. Verification first. The clinic obtains and documents the plan's TMS benefits, the medical-necessity criteria, prior-authorization requirements, and the patient's deductible and out-of-pocket-maximum status. Submitting the insurance verification form is the standard entry point.
2. Estimate the covered path. With verification in hand, the verification team produces a course-level out-of-pocket estimate — not a per-session figure — that accounts for deductible status, coinsurance, and the out-of-pocket maximum.
3. Compare to a documented self-pay quote. The self-pay course price is presented as a single number that covers the full clinical service (evaluation, mapping, sessions, taper, oversight). The comparison is course-to-course, not session-to-session.
4. Choose the financing structure. If the covered path is selected, the clinic submits prior authorization. If self-pay is selected, the patient and clinic agree on the payment structure — internal payment plan, medical-credit account, HSA/FSA, employer benefit, or a combination.
5. Document the agreement before treatment begins. Whichever path is chosen, the financial agreement should be in writing — total course cost, payment schedule, what is and is not included, refund policy if treatment is discontinued before course completion.

Patients who enter step 3 without completing steps 1 and 2 are the patients most likely to discover, partway through the course, that the other path would have cost less.

What this article does not do

This article does not quote a specific dollar amount for self-pay TMS at Healing TMS Clinic. The published range of approximately $8,000 to $15,000 cited above is a national benchmark drawn from clinical-registry and real-world economics data;¹ clinic-specific pricing varies by protocol, region, device, and current operating costs and is documented in the financial agreement at the time of treatment, not in an article that may be read months or years after writing. Verification and a current written quote from the clinic are the two documents that establish the actual numbers for any individual patient.

Key takeaways

• Self-pay TMS is a legitimate route for high-deductible, out-of-network, denied-but-clinically-appropriate, and privacy-preference patient profiles — but only after insurance verification has characterized the covered path.
• Published self-pay course costs for standard acute-phase rTMS series have historically fallen in the $8,000–$15,000 range in clinical-registry data;¹ clinic-specific pricing varies.
• A self-pay course price typically covers the initial psychiatric evaluation, motor-threshold mapping, 30–36 acute-phase sessions, taper sessions, and ongoing clinical oversight — line-item comparison across clinics matters.
• Financing structures used in psychiatric practice include internal payment plans, third-party medical-credit accounts, HSA and FSA funds, and employer wellness benefits; HSA/FSA dollars are pre-tax and TMS for a qualifying mental-health diagnosis is an eligible expense under IRS Publication 502.³
• Coverage for TMS under Medicare is governed by Local Coverage Determinations issued by the Medicare Administrative Contractors — there is no National Coverage Determination — and most major commercial payers cover TMS for documented major depressive disorder.²
• The decision framework is verify, estimate the covered path, compare to a self-pay quote, choose the financing structure, document the agreement in writing — in that order.

For patients in Anaheim, Orange County, and the broader 30-mile radius weighing the self-pay path, the clinic's standard practice is verification first: submitting the insurance verification form produces a course-level cost estimate under the patient's plan, against which any self-pay quote can be compared in writing. The TMS therapy page describes the clinical service itself, and the treatment-resistant depression page describes the diagnostic context most TMS patients enter the clinic under.

Sources / Further reading